Galapagos creates new subscription right plan
January 13 2022 - 4:01PM
Mechelen, Belgium;
13 January
2022,
22.01
CET; regulated information –
Galapagos NV (Euronext &
NASDAQ: GLPG) announced today that its supervisory
board created 30,000 subscription rights under a new
employee subscription right
plan.
On 13 January 2022, the supervisory board of
Galapagos approved a subscription right plan intended for an
employee of a subsidiary of the Company (not intended for members
of the management board of the Company), within the framework of
the authorized capital. Under this subscription right plan, 30,000
subscription rights were created (subject to acceptance). The
subscription rights have an exercise term of eight years as of the
date of the offer and an exercise price of €46.18 (the closing
price of the Galapagos share on Euronext Amsterdam and Brussels on
the day preceding the date of the offer). Further details are
available on the Galapagos website.
Galapagos’ total share capital currently amounts
to €354,582,005.11; the total number of securities conferring
voting rights is 65,552,721, which is also the total number of
voting rights (the “denominator”), and all securities conferring
voting rights and all voting rights are of the same category. The
total number of rights to subscribe to not yet issued securities
conferring voting rights is (i) 8,579,287 subscription rights under
several outstanding employee subscription right plans, which equals
8,579,287 voting rights that may result from the exercise of those
subscription rights, and (ii) one subscription right issued to
Gilead Therapeutics to subscribe for a maximum number of shares
that is sufficient to bring the shareholding of Gilead and its
affiliates to 29.9% of the actually issued and outstanding shares
after the exercise of the subscription right. This excludes the
30,000 subscription rights of the newly issued subscription right
plan, which were created subject to acceptance. Galapagos does not
have any convertible bonds or shares without voting rights
outstanding.
About
GalapagosGalapagos NV discovers, develops, and
commercializes small molecule medicines with novel modes of action.
Our pipeline comprises discovery through Phase 3 programs in
inflammation, fibrosis, and other indications. Our ambition is to
become a leading global biopharmaceutical company focused on the
discovery, development, and commercialization of innovative
medicines. More information at www.glpg.com.
ContactInvestors:Sofie
Van GijselHead of Investor Relations+1 781 296 1143
Sandra CauwenberghsDirector Investor Relations+32 495 58 46
63ir@glpg.com
Media:Marieke VermeerschHead of Corporate
Communication+32 479 490 603communications@glpg.com
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are
not guarantees of future results. These forward-looking
statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update
any forward-looking statements in this document, unless
specifically required by law or regulation.
- Galapagos creates new subscription right plan
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024